All In Biotech

Free tool

FAERS Monitor: Austedo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209885 or its brand name (Austedo, Deutetrabenazine). Reports on generic versions are filed under their own applications.

Reports

5,937

Serious

2,709

46% of reports

Hospitalization

817

Death reported

498

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective778
  • death435
  • depression388
  • dyskinesia386
  • tremor294
  • product use issue280
  • somnolence271
  • suicidal ideation260
  • fall255
  • insomnia255
  • product use in unapproved indication255
  • fatigue248
  • off label use247
  • tardive dyskinesia189
  • dizziness180

Reports by year received

View as table
YearReports
20161
201786
2018405
2019601
2020708
2021778
2022527
2023503
2024950
2025780
2026598

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,222 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dyskinesiaSignal38634.030.812,222
tardive dyskinesiaSignal18923.920.84,100
suicidal ideationSignal26010.19.02,123
tremorSignal2946.35.61,309
depressionSignal3886.05.51,645
product use issueSignal2805.34.7976
somnolenceSignal2714.84.2811
product use in unapproved indicationSignal2553.63.2493
insomniaSignal2553.43.0433
fallSignal2552.72.4279
drug ineffectiveSignal7782.12.0472
death4351.81.6157
dizziness1801.31.111
fatigue2481.11.04
off label use2471.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.